RayKnowChina Research Map
Shortlist0

RecruitingOesophageal squamous cell carcinomaPhase 2

Registered title, quoted from ClinicalTrials.gov

Nimotuzumab Plus Definite Chemoradiotherapy(dCRT) in Elderly Patients With Esophageal Squamous Cell Carcinoma

An open trial on oesophageal squamous cell carcinoma, registered on ClinicalTrials.gov. Led by Jiangsu Province Hospital; 0 other hospitals on this site are listed as study sites.

Status, phase and start date as registered on ClinicalTrials.gov on 8 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Hospitals in mainland China listed for this trial 1

Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.

  1. Lead sponsorJiangsu Province Hospital江苏省人民医院(南医大一附院)NanjingHospital page

The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov

Source: ClinicalTrials.gov record NCT06988956, read on 8 Nov 2026; hospital names matched to this site’s hospital list. How names are matched

Checklist for this trial 7

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (7 points)Hide the checklist
  1. 75 years to Not stated; sex: all

    Registered eligibility fields

  2. Oesophageal squamous cell carcinoma diagnosed by histology or cytology;

    Inclusion criterion 4

  3. According to the efficacy evaluation criteria of solid tumors (RECIST 1.1), at least one measurable lesion, and the measurable lesion should not receive local treatment such as radiotherapy (the lesion located in the previous radiotherapy area can also be selected if the progression is confirmed and meets the RECIST1.1 criteria);

    Inclusion criterion 5

  4. The ECOG score is 0-1 point;

    Inclusion criterion 3

  5. ANC≥1.5×109/L;

    Inclusion criterion 11

  6. History of other malignant tumors (except for cured cervical carcinoma in situ or basal cell carcinoma of the skin and other malignant tumors that have been cured for more than 5 years);

    Exclusion criterion 5

  7. Pregnant or lactating women;

    Exclusion criterion 11

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: stage or severity, as the trial defines it; scans and measurable lesions.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT06988956, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Inclusion Criteria:

  • The subject volunteered to join the study, signed the informed consent form, had good compliance, and cooperated with the follow-up;
  • Age 70 or above, male or female;
  • The ECOG score is 0-1 point;
  • Oesophageal squamous cell carcinoma diagnosed by histology or cytology;
  • According to the efficacy evaluation criteria of solid tumors (RECIST 1.1), at least one measurable lesion, and the measurable lesion should not receive local treatment such as radiotherapy (the lesion located in the previous radiotherapy area can also be selected if the progression is confirmed and meets the RECIST1.1 criteria);
  • Stage II-IVB (IVB stage only includes supraclavicular/abdominal lymph node metastasis, does not include any other distant metastasis), can tolerate synchronous radiotherapy, chemotherapy, and targeted therapy
  • Expected survival time of 6 months;
  • Main organ function is normal, that is, meet the following criteria:
  • Blood routine examination:
  • HBG≥90g/L;
  • ANC≥1.5×109/L;
  • PLT ≥80×109/L; 2) Biochemical examination:

a.ALB≥30g/L; B. ALT and AST≤2.5ULN; ALT and AST 5 ULN; c.TBIL≤1.5ULN; D. Plasma Cr≤1.5ULN or creatinine clearance (CCr) of 60 ml/min; 9. Echocardiographic assessment: left ventricular ejection fraction (LVEF) low normal value (50%); 10. Women of childbearing age should agree to use contraception (e. g. intrauterine devices, contraceptives or condoms) during the study and within 6 months after the study; serum or urine pregnancy tests were negative within 7 days before study enrollment and must be non-lactating patients; men who agree to use contraception during the study and within 6 months after the end of the study period.

Exclusion Criteria:

  • Received EGFR mAb and EGFR-TKI within half a year;
  • Participated in other interventional clinical trials within 30 days before screening;
  • Have serious concurrent diseases, such as heart failure, high risk of uncontrolled arrhythmia, severe myocardial infarction, intractable hypertension, renal failure (CKD-4 and above), thyroid insufficiency, mental illness, diabetes, severe chronic diarrhea (more than 7 times a day) and the researchers think not suitable to participate in the clinical research;
  • Patients with brain metastases with symptoms or symptom control time for less than 3 months;
  • History of other malignant tumors (except for cured cervical carcinoma in situ or basal cell carcinoma of the skin and other malignant tumors that have been cured for more than 5 years);
  • presence of active infection or active infectious diseases;
  • The presence of multilevel esophageal malignancy or signs of esophageal fistula and perforation;
  • Patients whose imaging shows that the tumor has invaded important blood vessels or whose tumor is likely to invade important blood vessels during the subsequent study;
  • Those allergic to the use of drugs or their ingredients in this regimen;
  • Grade 2 peripheral neurological disease or hearing loss according to the criteria of common adverse event terms (NCI CTCAE V5.0);
  • Pregnant or lactating women;
  • Patients with a history of psychiatric substance abuse and unable to quit or with mental disorders;
  • The investigator is not considered fit to join the investigator; Unwilling to participate in the study or unable to sign the informed consent form

Quoted from ClinicalTrials.gov, NCT06988956, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT06988956, read on 8 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT06988956